Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 16 for:    sage | Major Depressive Disorder
Previous Study | Return to List | Next Study

A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03864614
Recruitment Status : Active, not recruiting
First Posted : March 6, 2019
Last Update Posted : March 22, 2021
Sponsor:
Information provided by (Responsible Party):
Sage Therapeutics

Brief Summary:
This is a Phase 3, open-label, 1-year study of the safety, tolerability, and need for re-treatment with SAGE-217 in adult participants with MDD.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Drug: SAGE-217 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1200 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With SAGE-217 in Adult Subjects With Major Depressive Disorder
Actual Study Start Date : February 27, 2019
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : November 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: SAGE-217 Drug: SAGE-217
SAGE-217




Primary Outcome Measures :
  1. Safety and tolerability of the initial treatment with SAGE-217 and/or re-treatment with SAGE-217, as assessed by the incidence and severity of adverse events. [ Time Frame: 52 Weeks ]
  2. Safety and tolerability of the initial treatment with SAGE-217 and/or re-treatment with SAGE-217, as assessed by the incidence of clinically significant changes from baseline in clinical laboratory measures. [ Time Frame: 52 Weeks ]
  3. Safety and tolerability of the initial treatment with SAGE-217 and/or re-treatment with SAGE-217, as assessed by the incidence of clinically significant changes from baseline in vital signs. [ Time Frame: 52 Weeks ]
  4. Safety and tolerability of the initial treatment with SAGE-217 and/or re-treatment with SAGE-217, as assessed by the incidence of clinically significant changes from baseline in electrocardiograms (ECGs). [ Time Frame: 52 Weeks ]
  5. The safety and tolerability of the initial treatment with SAGE-217 and/or re-treatment with SAGE-217, as assessed by suicidal ideation and behavior using the Columbia Suicide Severity Rating Scale (C-SSRS). [ Time Frame: 52 Weeks ]
    The C-SSRS consists of a baseline evaluation that assesses the lifetime experience of the participants with suicidal ideation and behavior, and a post-baseline evaluation that focuses on suicidality since the last study visit. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe).


Secondary Outcome Measures :
  1. The need for re-treatment with SAGE-217 as assessed by the time to first re-treatment. [ Time Frame: Up to 52 weeks ]
  2. The need for re-treatment with SAGE-217 as assessed by the number of participants achieving the requirements for re-treatment. [ Time Frame: Up to 52 weeks ]
  3. The need for re-treatment with SAGE-217 as assessed by the number of re-treatment cycles for each participant. [ Time Frame: Up to 52 weeks ]
  4. The response of initial treatment and/or re-treatment as assessed by change from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D) score. [ Time Frame: Up to 52 weeks ]
    The 17-item HAM-D scale is used for measuring severity of depression. The HAM-D comprises individual ratings of the following symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression.

  5. The response of initial treatment and/or re-treatment as assessed by percent of participants achieving HAM-D response at the end of each 14-day treatment period, defined as a ≥50% reduction in HAM-D score from baseline. [ Time Frame: Up to 52 weeks ]
    The 17-item HAM-D scale is used for measuring severity of depression. The HAM-D comprises individual ratings of the following symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression.

  6. The response of initial treatment and/or re-treatment as assessed by percent of participants achieving HAM-D remission at the end of each 14-day treatment (initial and/or re-treatment) period, defined as HAM-D total score ≤7. [ Time Frame: Up to 52 weeks ]
    The 17-item HAM-D scale is used for measuring severity of depression. The HAM-D total score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression.

  7. The response of initial treatment and/or re-treatment as assessed by percent of participants achieving Clinical Global Impression - Improvement (CGI-I) score. [ Time Frame: Up to 52 weeks ]
    The CGI-I employs a 7-point Likert scale to measure the overall improvement in the participant's condition posttreatment. The Investigator will rate the participant's total improvement compared to baseline, whether or not it is due entirely to drug treatment. Response choices include: 0=not assessed, 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse.

  8. The response of initial treatment and/or re-treatment as assessed by change from baseline in Clinical Global Impression - Severity (CGI-S) score. [ Time Frame: Up to 52 weeks ]
    The CGI-S uses a 7-point Likert scale to rate the severity of the participant's mental illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating as 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=extremely ill.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participant has a diagnosis of MDD as diagnosed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Clinical Trial Version (SCID-5-CT), with symptoms that have been present for at least a 4-week period.
  2. Participant is in good physical health and has no clinically significant findings, as determined by the Investigator, on physical examination, 12-lead electrocardiogram (ECG), or clinical laboratory tests.
  3. Participant has a Montgomery-Åsberg Depression Rating Scale (MADRS) total score of ≥28 and a HAM-D total score of ≥20 at Screening and Day 1 (prior to dosing).

Exclusion Criteria:

  1. Participant has attempted suicide associated with the current episode of MDD.
  2. Participant has a medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.
  3. Participant has had vagus nerve stimulation, electroconvulsive therapy, or has taken ketamine (including esketamine) within the current major depressive episode.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03864614


Locations
Hide Hide 67 study locations
Layout table for location information
United States, Alabama
Sage Investigational Site
Dothan, Alabama, United States, 36303
United States, Arizona
Sage Investigational Site
Phoenix, Arizona, United States, 85012
United States, Arkansas
Sage Investigational Site
Little Rock, Arkansas, United States, 72211
United States, California
Sage Investigational Site
Anaheim, California, United States, 92805
Sage Investigational Site
Cerritos, California, United States, 90703
Sage Investigational Site
Costa Mesa, California, United States, 92626
Sage Investigational Site
Glendale, California, United States, 91206
Sage Investigational Site
Irvine, California, United States, 92614
Sage Investigational Site
Los Alamitos, California, United States, 90720
Sage Investigational Site
Newport Beach, California, United States, 92660
Sage Investigational Site
Oceanside, California, United States, 92056
Sage Investigational Site
Orange, California, United States, 92868
Sage Investigational Site
Riverside, California, United States, 92503
Sage Investigational Site
San Diego, California, United States, 92103
Sage Investigational Site
Temecula, California, United States, 92591
Sage Investigational Site
Torrance, California, United States, 90502
United States, Colorado
Sage Investigational Site
Colorado Springs, Colorado, United States, 80910
Sage Investigational Site
Denver, Colorado, United States, 80209
United States, Connecticut
Sage Investigational Site
Cromwell, Connecticut, United States, 06416
Sage Investigational Site
New Haven, Connecticut, United States, 06511
Sage Investigational Site
Norwich, Connecticut, United States, 06360
United States, Florida
Sage Investigational Site
Brandon, Florida, United States, 33511
Sage Investigational Site
Coral Springs, Florida, United States, 33067
Sage Investigational Site
Hialeah, Florida, United States, 33012
Sage Investigational Site
Hialeah, Florida, United States, 33015
Sage Investigational Site
Jacksonville, Florida, United States, 32256
Sage Investigational Site
Lakeland, Florida, United States, 33803
Sage Investigational Site
Miami, Florida, United States, 33122
Sage Investigational Site
Miami, Florida, United States, 33175
Sage Investigational Site
Orlando, Florida, United States, 32801
Sage Investigational Site
Pensacola, Florida, United States, 32502
Sage Investigational Site
Tampa, Florida, United States, 33634
United States, Georgia
Sage Investigational Site
Alpharetta, Georgia, United States, 30022
Sage Investigational Site
Atlanta, Georgia, United States, 30331
Sage Investigational Site
Marietta, Georgia, United States, 30060
Sage Investigational Site
Savannah, Georgia, United States, 31405
United States, Illinois
Sage Investigational Site
Chicago, Illinois, United States, 60634
Sage Investigational Site
Chicago, Illinois, United States, 60640
United States, Kansas
Sage Investigational Site
Wichita, Kansas, United States, 67214
United States, Maryland
Sage Investigational Site
Towson, Maryland, United States, 21204
United States, Massachusetts
Sage Investigational Site
Watertown, Massachusetts, United States, 02472
United States, Missouri
Sage Investigational Site
Saint Charles, Missouri, United States, 63304
United States, Nebraska
Sage Investigational Site
Lincoln, Nebraska, United States, 68526
United States, New Jersey
Sage Investigational Site
Cherry Hill, New Jersey, United States, 08002
Sage Investigational site
Marlton, New Jersey, United States, 08053
Sage Investigational Site
Princeton, New Jersey, United States, 08540
United States, New Mexico
Sage Investigational Site
Albuquerque, New Mexico, United States, 87109
United States, New York
Sage Investigational Site
Brooklyn, New York, United States, 11229
Sage Investigational Site
Brooklyn, New York, United States, 11235
Sage Investigational Site
Glen Oaks, New York, United States, 11004
Sage Investigational Site
Mount Kisco, New York, United States, 10549
Sage Investigational Site
New York, New York, United States, 10017
Sage Investigational Site
New York, New York, United States, 10019
United States, Ohio
Sage Investigational Site
Beachwood, Ohio, United States, 44122
Sage Investigational Site
Cincinnati, Ohio, United States, 45212
Sage Investigational site
Cincinnati, Ohio, United States, 45215
Sage Investigational Site
North Canton, Ohio, United States, 44720
United States, Oklahoma
Sage Investigational Site
Oklahoma City, Oklahoma, United States, 73112
United States, Oregon
Sage Investigational Site
Salem, Oregon, United States, 97301
United States, Pennsylvania
Sage Investigational Site
Norristown, Pennsylvania, United States, 19403
United States, Texas
Sage Investigational Site
Austin, Texas, United States, 78737
Sage Investigational Site
Austin, Texas, United States, 78759
Sage Investigational Site
Dallas, Texas, United States, 75231
Sage Investigational Site
Houston, Texas, United States, 77081
Sage Investigational Site
San Antonio, Texas, United States, 78229
Sage Investigational Site
Wichita Falls, Texas, United States, 76309
United States, Washington
Sage Investigational Site
Bellevue, Washington, United States, 98007
Sponsors and Collaborators
Sage Therapeutics
Layout table for additonal information
Responsible Party: Sage Therapeutics
ClinicalTrials.gov Identifier: NCT03864614    
Other Study ID Numbers: 217-MDD-303
First Posted: March 6, 2019    Key Record Dates
Last Update Posted: March 22, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Data sharing will be consistent with the Results submission policy of ClinicalTrials.gov

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms